Gerald Willimsky
YOU?
Author Swipe
View article: Table S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Table S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Table S1A. Peptides; Table S1B. NetMHCIIpan 4.0; Table S1C. NetMHC 4.0
View article: Table S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Table S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Table S3. Primer for single cell T cell receptor sequencing.
View article: Table S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Table S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Table S2. Murine primers for evaluation of Cic expression.
View article: A CD22-Specific T-Cell Receptor Enables Effective Adoptive T-Cell Therapy for B-cell malignancies
A CD22-Specific T-Cell Receptor Enables Effective Adoptive T-Cell Therapy for B-cell malignancies Open
CD19 chimeric antigen receptor (CAR) T-cell therapy has become the standard of care in relapse and/or refractory B-cell malignancies. 30-60% of patients experience relapsed disease due to the emergence of CD19low or CD19negative tumor cell…
View article: Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer
Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer Open
Background Personalized immunotherapy of pancreatic ductal adenocarcinoma (PDAC) through T-cell mediated targeting of tumor-specific, mutanome-encoded neoepitopes may offer new opportunities to combat this disease, in particular by counter…
View article: Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire Open
Background The development of T-cell receptor (TCR)-based T-cell therapies is hampered by the difficulties in identifying therapeutically effective tumor-specific TCRs from the natural repertoire of a patient’s cancer-specific T cells. Met…
View article: T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy
T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy Open
BCR-ABL kinase is the major oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs), which are highly potent in targeting BCR-ABL, are currently used as first-line treatment. Although TKIs are effective, drug …
View article: A facility for laboratory mice with a natural microbiome at Charité – Universitätsmedizin Berlin
A facility for laboratory mice with a natural microbiome at Charité – Universitätsmedizin Berlin Open
View article: A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patientswith advanced multiple myeloma
A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patientswith advanced multiple myeloma Open
Not available.
View article: Data from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Data from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Purpose:Gliomas are intrinsic brain tumors with a high degree of constitutive and acquired resistance to standard therapeutic modalities such as radiotherapy and alkylating chemotherapy. Glioma subtypes are recognized by characteristic mut…
View article: Table S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Table S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Table S1A. Peptides; Table S1B. NetMHCIIpan 4.0; Table S1C. NetMHC 4.0
View article: Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Supplementary Figure 1: T cell responses in A2.DR1 and DR4 mice after peptide vaccination with potential shared neoepitopes. A. Predicted binding affinity for selected amino acid alterations for HLA-A*0201 determined by NetMHC 4.0. B, C. Q…
View article: Table S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Table S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Table S1A. Peptides; Table S1B. NetMHCIIpan 4.0; Table S1C. NetMHC 4.0
View article: Table S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Table S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Table S2. Murine primers for evaluation of Cic expression.
View article: Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Supplementary Figure 3: T cell effector functions of TCR-transgenic T cells targeting CICR215W. A. Venn diagram of shared TCR-β sequences in T cell lines generated from n = 4 CICR215W vaccinated mice. B. Normalized IFN-γ production of di…
View article: Table S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Table S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Table S3. Primer for single cell T cell receptor sequencing.
View article: Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Supplementary Figure 1: T cell responses in A2.DR1 and DR4 mice after peptide vaccination with potential shared neoepitopes. A. Predicted binding affinity for selected amino acid alterations for HLA-A*0201 determined by NetMHC 4.0. B, C. Q…
View article: Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Supplementary Figure 2: Molecular features of A2.DR1 MHC-humanized gliomas. A. Verification of the CRISPR-Cas9-mediated functional KO of p53 and Nf1 in the A2.DR1 glioma cell line. B. Copy number variations (CNVs) in the A2.DR1 glioma cell…
View article: Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Supplementary Figure 2: Molecular features of A2.DR1 MHC-humanized gliomas. A. Verification of the CRISPR-Cas9-mediated functional KO of p53 and Nf1 in the A2.DR1 glioma cell line. B. Copy number variations (CNVs) in the A2.DR1 glioma cell…
View article: Table S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Table S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Table S3. Primer for single cell T cell receptor sequencing.
View article: Data from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Data from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Purpose:Gliomas are intrinsic brain tumors with a high degree of constitutive and acquired resistance to standard therapeutic modalities such as radiotherapy and alkylating chemotherapy. Glioma subtypes are recognized by characteristic mut…
View article: Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Supplementary Figure 3: T cell effector functions of TCR-transgenic T cells targeting CICR215W. A. Venn diagram of shared TCR-β sequences in T cell lines generated from n = 4 CICR215W vaccinated mice. B. Normalized IFN-γ production of di…
View article: Table S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Table S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Open
Table S2. Murine primers for evaluation of Cic expression.
View article: Early protective effect of a (“pan”) coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration
Early protective effect of a (“pan”) coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration Open
Introduction The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the danger posed by human coronaviruses. Rapid emergence of immunoevasive variants and wan…
View article: Data from Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival
Data from Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival Open
Tumor-infiltrating CD8+ T cells are associated with improved survival of patients with Merkel cell carcinoma (MCC), an aggressive skin cancer causally linked to Merkel cell polyomavirus (MCPyV). However, CD8+ T-cell i…
View article: Data from Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival
Data from Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival Open
Tumor-infiltrating CD8+ T cells are associated with improved survival of patients with Merkel cell carcinoma (MCC), an aggressive skin cancer causally linked to Merkel cell polyomavirus (MCPyV). However, CD8+ T-cell i…
View article: Supplementary Figures 1 through 6, and Supplementary Tables 1 through 3 from Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival
Supplementary Figures 1 through 6, and Supplementary Tables 1 through 3 from Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival Open
Figure S1. KLL-specific TCR diversity in PBMC is not correlated with the magnitude of KLL-specific responses. Figure S2. Clonality of KLL-specific T cell repertoire in PBMC of MCC patients does not correlate with disease outcome. Figure S3…
View article: Supplementary Figures 1 through 6, and Supplementary Tables 1 through 3 from Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival
Supplementary Figures 1 through 6, and Supplementary Tables 1 through 3 from Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival Open
Figure S1. KLL-specific TCR diversity in PBMC is not correlated with the magnitude of KLL-specific responses. Figure S2. Clonality of KLL-specific T cell repertoire in PBMC of MCC patients does not correlate with disease outcome. Figure S3…
View article: methods from Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
methods from Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy Open
constructs, murine HCC model, spheroid and imaging, RCC tissue pathology
View article: Supplemental Figures S1-S7 from ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice
Supplemental Figures S1-S7 from ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice Open
File contains supplementary figures showing TAP-specific peptide translocation, growth of WT and Erap1-/- HCC in different recipients, gating strategy for T cell analysis, antigen-dependent T cell expansion, rejection of WT and Erap1-/- HC…